<SEC-DOCUMENT>0000947871-21-000248.txt : 20210219
<SEC-HEADER>0000947871-21-000248.hdr.sgml : 20210219
<ACCEPTANCE-DATETIME>20210219164759
ACCESSION NUMBER:		0000947871-21-000248
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210217
FILED AS OF DATE:		20210219
DATE AS OF CHANGE:		20210219

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Thompson Peter A.
		CENTRAL INDEX KEY:			0001357522

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37719
		FILM NUMBER:		21656639

	MAIL ADDRESS:	
		STREET 1:		C/O ANTHERA PHARMACEUTICALS, INC.
		STREET 2:		25801 INDUSTRIAL BOULEVARD, SUITE B
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545

	FORMER NAME:	
		FORMER CONFORMED NAME:	Thompson Peter A
		DATE OF NAME CHANGE:	20060327

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Corvus Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001626971
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				464670809
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		863 MITTEN ROAD
		STREET 2:		SUITE 102
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
		BUSINESS PHONE:		(650) 900-4520

	MAIL ADDRESS:	
		STREET 1:		863 MITTEN ROAD
		STREET 2:		SUITE 102
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-02-17</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001626971</issuerCik>
        <issuerName>Corvus Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>CRVS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001357522</rptOwnerCik>
            <rptOwnerName>Thompson Peter A.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CORVUS PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>860 MITTEN ROAD, SUITE 102</rptOwnerStreet2>
            <rptOwnerCity>BURLINGAME</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94010</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock, $0.0001 par value</value>
            </securityTitle>
            <transactionDate>
                <value>2021-02-17</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>1285714</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>3.50</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>8053298</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnotes</value>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">These shares of the Issuer's common stock (&quot;Shares&quot;) were purchased in a registered public offering.</footnote>
        <footnote id="F2">These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (&quot;OPI V&quot;). OrbiMed Capital GP V LLC (&quot;GP V&quot;) is the general partner of OPI V, and OrbiMed Advisors LLC (&quot;OrbiMed Advisors&quot;), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V.</footnote>
        <footnote id="F3">Each of the Reporting Person, GP V, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V, or OrbiMed Advisors are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Peter Thompson</signatureName>
        <signatureDate>2021-02-19</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
